Corticosteroids in Inflammatory Bowel Disease Patients: A Practical Guide for Physicians

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Inflammatory Bowel Diseases (IBD) present complex challenges with unknown causes and immune system dysregulation.
• Corticosteroids have been the standard treatment for moderate to severe IBD since the 1950s.
• Current steroid use in IBD is often empirical, lacking robust evidence for optimal therapeutic schemes.

Purpose of the Study:

• To review the efficacy and safety of conventional and low-bioavailability steroids in Inflammatory Bowel Disease (IBD) patients.
• To evaluate current literature evidence for steroid use in IBD management.
• To provide practical guidance for the appropriate clinical application of steroids in IBD, aligned with existing guidelines.

Main Methods:

• Comprehensive literature review of studies on steroid efficacy and safety in IBD.
• Analysis of evidence for both conventional corticosteroids and low-bioavailability steroids.
• Evaluation of clinical guidelines for steroid management in IBD.

Main Results:

• Conventional steroids are effective but associated with significant side effects and limited long-term impact on IBD natural history.
• Low-bioavailability steroids demonstrate comparable efficacy with an improved safety profile due to high peripheral receptor affinity and hepatic metabolism.
• Steroid-sparing is a key objective in IBD management, necessitating careful consideration of treatment options.

Conclusions:

• Low-bioavailability steroids represent a valuable therapeutic option for IBD, offering a better safety profile than conventional steroids.
• Optimizing steroid use in IBD requires balancing efficacy with minimizing adverse effects.
• Adherence to clinical guidelines is essential for the correct and effective application of steroid therapies in IBD patients.